Crinetics Book Value Per Share from 2010 to 2025

CRNX Stock

USD 37.35 0.87 2.38%

Crinetics Pharmaceuticals Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to 4.61 in 2025. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Crinetics Pharmaceuticals according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

8.36

Current Value

4.61

Quarterly Volatility

4.62908027

Credit Downgrade

Yuan Drop

Covid

Check Crinetics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 16.2 M, Interest Income of 16.2 M or Depreciation And Amortization of 760.2 K, as well as many indicators such as Price To Sales Ratio of 918, Dividend Yield of 0.0 or PTB Ratio of 3.62. Crinetics financial statements analysis is a perfect complement when working with Crinetics Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Crinetics Pharmaceuticals Correlation against competitors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Latest Crinetics Pharmaceuticals' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Crinetics Pharmaceuticals over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Crinetics Pharmaceuticals' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crinetics Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 10.30 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Crinetics Book Value Per Share Regression Statistics

	Arithmetic Mean	3.52
	Geometric Mean	1.89
	Coefficient Of Variation	131.43
	Mean Deviation	4.05
	Median	4.61
	Standard Deviation	4.63
	Sample Variance	21.43
	Range	14.2784
	R-Value	0.73
	Mean Square Error	10.86
	R-Squared	0.53
	Significance	0
	Slope	0.71
	Total Sum of Squares	321.43

Crinetics Book Value Per Share History

	2025	4.61
	2024	8.36
	2023	9.28
	2022	6.09
	2021	8.64
	2020	5.55
	2019	4.85

Other Fundumenentals of Crinetics Pharmaceuticals

Tangible Book Value Per Share

Crinetics Pharmaceuticals Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Short Term Investments	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue
Total Assets		0.67	0.93	-0.04	-0.97	0.81	-0.73	0.97	-0.73	0.81	0.91	-0.73	1.0	0.96	0.99	0.71	1.0	1.0	0.93	-0.79	0.99	0.88
Total Stockholder Equity	0.67		0.38	0.48	-0.59	0.3	-0.72	0.83	-0.72	0.26	0.87	-0.72	0.65	0.83	0.65	0.15	0.63	0.64	0.81	-0.22	0.65	0.61
Net Tangible Assets	0.93	0.38		-0.32	-0.92	0.86	-0.56	0.82	-0.56	0.92	0.71	-0.56	0.95	0.81	0.92	0.84	0.96	0.95	0.77	-0.88	0.92	0.78
Net Debt	-0.04	0.48	-0.32		0.02	-0.12	-0.21	0.15	-0.21	-0.36	0.3	-0.21	-0.07	0.16	-0.02	-0.38	-0.1	-0.08	0.28	0.37	-0.02	0.3
Retained Earnings	-0.97	-0.59	-0.92	0.02		-0.86	0.59	-0.92	0.59	-0.77	-0.88	0.59	-0.97	-0.92	-0.98	-0.7	-0.97	-0.97	-0.92	0.82	-0.98	-0.92
Accounts Payable	0.81	0.3	0.86	-0.12	-0.86		-0.34	0.72	-0.34	0.85	0.62	-0.34	0.81	0.71	0.82	0.89	0.82	0.81	0.67	-0.91	0.82	0.77
Long Term Debt	-0.73	-0.72	-0.56	-0.21	0.59	-0.34		-0.78	1.0	-0.45	-0.79	1.0	-0.72	-0.78	-0.72	-0.29	-0.7	-0.71	-0.78	0.41	-0.72	-0.66
Net Receivables	0.97	0.83	0.82	0.15	-0.92	0.72	-0.78		-0.78	0.7	0.97	-0.78	0.96	1.0	0.96	0.6	0.95	0.96	0.97	-0.68	0.96	0.87
Long Term Debt Total	-0.73	-0.72	-0.56	-0.21	0.59	-0.34	1.0	-0.78		-0.45	-0.79	1.0	-0.72	-0.78	-0.72	-0.29	-0.7	-0.71	-0.78	0.41	-0.72	-0.66
Capital Surpluse	0.81	0.26	0.92	-0.36	-0.77	0.85	-0.45	0.7	-0.45		0.53	-0.45	0.82	0.69	0.77	0.97	0.84	0.82	0.58	-0.89	0.77	0.61
Total Liab	0.91	0.87	0.71	0.3	-0.88	0.62	-0.79	0.97	-0.79	0.53		-0.79	0.9	0.97	0.92	0.42	0.88	0.89	0.99	-0.55	0.92	0.89
Short Long Term Debt	-0.73	-0.72	-0.56	-0.21	0.59	-0.34	1.0	-0.78	1.0	-0.45	-0.79		-0.72	-0.78	-0.72	-0.29	-0.7	-0.71	-0.78	0.41	-0.72	-0.66
Total Current Assets	1.0	0.65	0.95	-0.07	-0.97	0.81	-0.72	0.96	-0.72	0.82	0.9	-0.72		0.95	0.99	0.72	1.0	1.0	0.92	-0.8	0.99	0.88
Short Term Debt	0.96	0.83	0.81	0.16	-0.92	0.71	-0.78	1.0	-0.78	0.69	0.97	-0.78	0.95		0.95	0.59	0.95	0.95	0.96	-0.67	0.95	0.87
Common Stock	0.99	0.65	0.92	-0.02	-0.98	0.82	-0.72	0.96	-0.72	0.77	0.92	-0.72	0.99	0.95		0.68	0.98	0.99	0.94	-0.81	1.0	0.91
Property Plant Equipment	0.71	0.15	0.84	-0.38	-0.7	0.89	-0.29	0.6	-0.29	0.97	0.42	-0.29	0.72	0.59	0.68		0.75	0.72	0.46	-0.91	0.68	0.51
Net Invested Capital	1.0	0.63	0.96	-0.1	-0.97	0.82	-0.7	0.95	-0.7	0.84	0.88	-0.7	1.0	0.95	0.98	0.75		1.0	0.91	-0.81	0.98	0.86
Net Working Capital	1.0	0.64	0.95	-0.08	-0.97	0.81	-0.71	0.96	-0.71	0.82	0.89	-0.71	1.0	0.95	0.99	0.72	1.0		0.92	-0.8	0.99	0.87
Short Term Investments	0.93	0.81	0.77	0.28	-0.92	0.67	-0.78	0.97	-0.78	0.58	0.99	-0.78	0.92	0.96	0.94	0.46	0.91	0.92		-0.58	0.94	0.95
Deferred Long Term Liab	-0.79	-0.22	-0.88	0.37	0.82	-0.91	0.41	-0.68	0.41	-0.89	-0.55	0.41	-0.8	-0.67	-0.81	-0.91	-0.81	-0.8	-0.58		-0.81	-0.63
Capital Stock	0.99	0.65	0.92	-0.02	-0.98	0.82	-0.72	0.96	-0.72	0.77	0.92	-0.72	0.99	0.95	1.0	0.68	0.98	0.99	0.94	-0.81		0.91
Current Deferred Revenue	0.88	0.61	0.78	0.3	-0.92	0.77	-0.66	0.87	-0.66	0.61	0.89	-0.66	0.88	0.87	0.91	0.51	0.86	0.87	0.95	-0.63	0.91

Click cells to compare fundamentals

About Crinetics Pharmaceuticals Financial Statements

Crinetics Pharmaceuticals investors use historical fundamental indicators, such as Crinetics Pharmaceuticals' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Crinetics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	8.36	4.61
Tangible Book Value Per Share	8.36	4.61

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC